KNSA - Kiniksa Pharmaceuticals, Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Kiniksa Pharmaceuticals, Ltd.

Clarendon House
2 Church Street
Hamilton HM 11
Bermuda
44-808-189-6257
http://www.kiniksa.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees111

Key Executives

NameTitlePayExercisedYear Born
Mr. Sanj K. PatelCEO & Chairman1.49MN/A1970
Mr. Stephen MahoneyPres & COO737.86kN/A1971
Dr. John F. PaoliniSr. VP & Chief Medical Officer628.53kN/A1965
Mr. Chris HeberligExec. VP, CFO & TreasurerN/AN/A1975
Mark Ragosa C.F.A.VP of Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis. The company's preclinical product candidates comprise KPL-404, a monoclonal antibody inhibitor of the CD40 co-stimulatory receptor; and KPL-045, a monoclonal antibody inhibitor of the CD30 ligand co-stimulatory molecule. Kiniksa Pharmaceuticals, Ltd. was founded in 2015 and is based in Hamilton, Bermuda.

Corporate Governance

Kiniksa Pharmaceuticals, Ltd.’s ISS Governance QualityScore as of June 25, 2019 is 10. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 10; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.